Sign in

Myeloproliferative neoplasms: trials that stopped early

Trials on Myeloproliferative neoplasms that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

31 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

    Reason given in the registry

    “FDA Clinical Hold”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2026.

    Ended
    Oct 2026
    Phase
    Phase 1
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT02530034
  2. Terminated

    Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

    Reason given in the registry

    “PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Oct 2026.

    Ended
    Mar 2025
    Phase
    Phase 2
    Run by
    University of Utah
    Registry record
    NCT03627403
  3. Withdrawn

    A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

    Reason given in the registry

    “PI request”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Oct 2026.

    Ended
    Jun 2026
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06597734
  4. Terminated

    RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Sept 2026.

    Ended
    Jun 2026
    Phase
    Phase 2
    Run by
    Ryvu Therapeutics SA
    Registry record
    NCT06397313
  5. Withdrawn

    Pacritinib With Aza for Upfront Myelodysplastic Syndrome

    Reason given in the registry

    “FDA requested significant changes to the study protocol”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Aug 2026.

    Phase
    Phase 1/2
    Run by
    Thomas Jefferson University
    Registry record
    NCT07387354
  6. Withdrawn

    Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

    Reason given in the registry

    “In alignment with company strategic direction.”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Jul 2026.

    Phase
    Phase 4
    Run by
    PharmaEssentia
    Registry record
    NCT06290765
  7. Terminated

    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

    Reason given in the registry

    “No longer a research question to answer.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2026.

    Ended
    May 2026
    Run by
    Masonic Cancer Center, University of Minnesota
    Registry record
    NCT01962636
  8. Terminated

    Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

    Reason given in the registry

    “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 May 2026.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT03246906
  9. Terminated

    Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

    Reason given in the registry

    “The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Apr 2026.

    Ended
    Feb 2025
    Phase
    Phase 1/2
    Run by
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT03878199
  10. Withdrawn

    Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

    Reason given in the registry

    “Drug Source Request”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Feb 2026.

    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06284460
  11. Terminated

    A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

    Reason given in the registry

    “Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Jan 2026.

    Ended
    Dec 2025
    Phase
    Phase 1/2
    Run by
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Registry record
    NCT06245941
  12. Terminated

    Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

    Reason given in the registry

    “Did not advance to Phase 2”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Dec 2025.

    Ended
    Jan 2025
    Phase
    Phase 1
    Run by
    H. Lee Moffitt Cancer Center and Research Institute
    Registry record
    NCT05127174
  13. Terminated

    P1101 in Treating Patients With Myelofibrosis

    Reason given in the registry

    “Study drug became commercially available”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Oct 2025.

    Ended
    Nov 2023
    Phase
    Phase 2
    Run by
    Mayo Clinic
    Registry record
    NCT02370329
  14. Terminated

    To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

    Reason given in the registry

    “The study was terminated due to futility.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2025.

    Ended
    Nov 2024
    Phase
    Phase 3
    Run by
    Incyte Corporation
    Registry record
    NCT04551066
  15. Terminated

    To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

    Reason given in the registry

    “The study was terminated due to futility.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 3
    Run by
    Incyte Corporation
    Registry record
    NCT04551053
  16. Terminated

    TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

    Reason given in the registry

    “This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Aug 2025.

    Ended
    Aug 2025
    Phase
    Phase 1
    Run by
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Registry record
    NCT06388759
  17. Terminated

    Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Aug 2025.

    Ended
    Aug 2024
    Phase
    Phase 1/2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04097821
  18. Terminated

    Connect® Myeloid Disease Registry

    Reason given in the registry

    “Business objectives have changed”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jul 2025.

    Ended
    Oct 2024
    Run by
    Celgene
    Registry record
    NCT01688011
  19. Terminated

    Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

    Reason given in the registry

    “Low accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Jul 2025.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    Weill Medical College of Cornell University
    Registry record
    NCT04103645
  20. Terminated

    Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

    Reason given in the registry

    “The study was stopped due to a business decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.

    Ended
    May 2024
    Phase
    Phase 2
    Run by
    NS Pharma, Inc.
    Registry record
    NCT04854096
  21. Withdrawn

    A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

    Reason given in the registry

    “0 participant accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 May 2025.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06619522
  22. Terminated

    Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

    Reason given in the registry

    “Terminated - alignment of strategic priorities”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Apr 2025.

    Ended
    Mar 2025
    Phase
    Phase 1
    Run by
    Blueprint Medicines Corporation
    Registry record
    NCT05609942
  23. Terminated

    A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

    Reason given in the registry

    “Slow accrual.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2024.

    Ended
    Nov 2023
    Phase
    Phase 3
    Run by
    Celgene
    Registry record
    NCT03755518
  24. Withdrawn

    Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

    Reason given in the registry

    “Lack of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2024.

    Ended
    Jun 2026
    Phase
    Phase 1
    Run by
    Leland Metheny
    Registry record
    NCT03939585
  25. Terminated

    Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

    Reason given in the registry

    “Closed by Sponsor”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2024.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Joseph Jurcic
    Registry record
    NCT05524857
  26. Terminated

    PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

    Reason given in the registry

    “Company Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Jan 2024.

    Ended
    Jan 2024
    Phase
    Phase 1
    Run by
    Prelude Therapeutics Incorporated
    Registry record
    NCT05107856
  27. Withdrawn

    A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

    Reason given in the registry

    “Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Nov 2023.

    Ended
    Jan 2026
    Phase
    Phase 2
    Run by
    Keros Therapeutics, Inc.
    Registry record
    NCT05927012
  28. Withdrawn

    Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

    Reason given in the registry

    “PI discretion”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Oct 2023.

    Ended
    Oct 2024
    Phase
    Phase 1/2
    Run by
    Case Comprehensive Cancer Center
    Registry record
    NCT04629651
  29. Withdrawn

    A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

    Reason given in the registry

    “Samus Therapeutics Closure”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2022.

    Ended
    Feb 2024
    Phase
    Phase 2
    Run by
    Samus Therapeutics, Inc.
    Registry record
    NCT05612633
  30. Withdrawn

    HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

    Reason given in the registry

    “Medigene transfered all rights to a new Sponsor”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2021.

    Ended
    Jul 2025
    Phase
    Phase 1
    Run by
    Medigene AG
    Registry record
    NCT04464889

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.